Turnstone Biologics Corp. (TSBX)

USD 0.45

(-10.36%)

Market Cap (In USD)

10.4 Million

Revenue (In USD)

19.3 Million

Net Income (In USD)

-55.2 Million

Avg. Volume

268.62 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.403-5.75
PE
-
EPS
-
Beta Value
0.0
ISIN
US90042W1009
CUSIP
90042W100
CIK
1764974
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Sammy J. Farah M.B.A., Ph.D.
Employee Count
-
Website
https://turnstonebio.com
Ipo Date
2023-07-21
Details
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.